<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03489239</url>
  </required_header>
  <id_info>
    <org_study_id>11729</org_study_id>
    <nct_id>NCT03489239</nct_id>
  </id_info>
  <brief_title>Entecavir to TAF Switch</brief_title>
  <official_title>Long-term Study to Observe Safety and Efficacy of TAF in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A research study to observe the safety, efficacy and tolerability of switching from Entecavir
      (ETV) to Tenofovir Alafenamide TAF in patients with chronic hepatitis B
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2017</start_date>
  <completion_date type="Anticipated">November 16, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Results of viral Hepatitis B DNA to be &lt;20 IU/mL</measure>
    <time_frame>48 weeks</time_frame>
    <description>The proportion of subjects with plasma HBV DNA levels below 20 IU/mL at week 48.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete viral suppression at study completion</measure>
    <time_frame>96 Weeks</time_frame>
    <description>The proportion of subjects with complete viral suppression, i.e., plasma HBV DNA level below 20 IU/mL at Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive eGFR changes at study completion compared to Baseline visit</measure>
    <time_frame>96 weeks</time_frame>
    <description>Change in eGFR from baseline to Week 96</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved Bone Mass Density at study completion</measure>
    <time_frame>96 weeks</time_frame>
    <description>% change from baseline in BMD at the hip and lumbar spine at Week 96.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SingleArm: TAF 25 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Alafenamide</intervention_name>
    <description>subjects switching from Entecavir to single arm TAF 25mg</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>TAF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects, adult male and female ≥18 years of age with chronic hepatitis B with or
             without compensated cirrhosis

          -  Maintained on Entecavir for a minimum of 48 weeks

          -  Viral suppression (HBV DNA &lt;20 IU/mL) for a minimum of 12 weeks prior to entry are
             eligible for this study.

          -  Estimated creatinine clearance ≥ 50 ml/min (using the Cockcroft-Gault method) based on
             serum creatinine and actual body weight as measured at the baseline evaluation.

        Exclusion Criteria:

          -  Subjects with known poor or non-compliance

          -  Subjects with co-infection with HCV or HIV subjects with decompensated cirrhosis and
             HCC will be excluded to participate in the study.

          -  Pregnant women and those who wish to become pregnant during the course of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hie-Won Hann, MD</last_name>
    <phone>215-955-5806</phone>
    <email>hie-won.hann@jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hie-Won Hann, MD</last_name>
      <phone>215-955-5806</phone>
      <email>hie-won.hann@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Grace Park, BA</last_name>
      <phone>215-955-5806</phone>
      <email>grace.park@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hie-Won Hann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2018</study_first_submitted>
  <study_first_submitted_qc>April 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2018</study_first_posted>
  <last_update_submitted>April 3, 2018</last_update_submitted>
  <last_update_submitted_qc>April 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

